Rationale Many studies have reported medication effects on alcohol cue-elicited brain activation or associations between such activation and subsequent drinking. However, few have combined the methodological rigor of a randomized clinical trial (RCT) with follow-up assessments to determine whether cue-elicited activation predicts relapse during treatment, the crux of alcoholism. Objectives This study analyzed functional magnetic resonance imaging (fMRI) data from 48 alcohol-dependent subjects enrolled in a 6-week RCT of an investigational pharmacotherapy. Methods Subjects were randomized, based on their level of alcohol withdrawal (AW) at study entry, to receive either a combination of gabapentin (GBP; up to 1,200 mg for 39 days) and flumazenil (FMZ) infusions (2 days) or two placebos. Midway through the RCT, subjects were administered an fMRI alcohol cue reactivity task. Results There were no main effects of medication or initial AW status on cue-elicited activation, but these factors interacted, such that the GBP/FMZ/higher AW and placebo/lower AW groups, which had previously been shown to have relatively reduced drinking, demonstrated greater dorsal anterior cingulate cortex (dACC) activation to alcohol cues. Further analysis suggested that this finding represented differences in task-related deactivation and was associated with greater control over alcohol-related thoughts. Among study completers, regardless of medication or AW status, greater left dorsolateral prefrontal cortex (DLPFC) activation predicted more post-scan heavy drinking. Conclusions These data suggest that alterations in taskrelated deactivation of dACC, a component of the default mode network, may predict better alcohol treatment response, while activation of DLPFC, an area associated with selective attention, may predict relapse drinking.
Introduction
Among individuals with alcohol dependence, functional magnetic resonance imaging (fMRI) studies have consistently demonstrated that alcohol-related stimuli (cues) elicit activation in brain regions associated with reward processing, including the ventral and dorsal striatum (VS and DS), medial and dorsolateral prefrontal cortex (mPFC and DLPFC), orbitofrontal cortex (OFC), anterior and posterior cingulate cortex (ACC and PCC), precuneus, and insula (for a review, see Schacht et al. 2013a) . Medications that reduce drinking among alcoholics have also been shown to reduce alcohol cue-elicited activation in several of these regions. An acute dose of amisulpride, an atypical dopamine antagonist, has been reported to reduce thalamic activation (Hermann et al. 2006 ). We previously reported that both naltrexone, a μ-opioid receptor antagonist, and aripiprazole, an atypical dopamine partial agonist, reduced VS activation (Myrick et al. 2008 (Myrick et al. , 2010 ) (although a follow-up study replicated the naltrexone finding only among individuals who carried a specific combination of genetic variants; Schacht et al. 2013b ). In the original naltrexone study, naltrexone, either alone or in combination with ondansetron, also reduced DS, mPFC, and OFC activation. Recently, Langosch et al. (2012) reported that acamprosate, an N-methyl-Daspartate modulator, had no effects on cue-elicited activation. However, with the exception of the negative acamprosate study, previous research has focused on acute or subacute treatment paradigms among non-treatment-seeking subjects. In these studies, little follow-up has been conducted to determine subjects' subsequent drinking behavior and how it might relate to the imaging data.
Irrespective of medication, several studies have reported prospective associations between cue-elicited brain activation and subsequent drinking behavior outside of the scanner. Among detoxified, treatment-seeking adult alcoholics, mPFC activation has been reported to be greater among those who subsequently relapse, while VS and midbrain activation have been reported to be greater among those who maintain abstinence (Beck et al. 2012; Grüsser et al. 2004) . VS and thalamic activation elicited by affectively positive (non-alcohol-related) visual stimuli have also been negatively associated with the subsequent frequency and amount of alcohol intake (Heinz et al. 2007) . Structural imaging studies have suggested volume reductions in mPFC, OFC, and parieto-occipital areas among adult alcoholics who relapse to heavy drinking after treatment (Beck et al. 2012; Cardenas et al. 2011; Rando et al. 2011) , and cortical perfusion in many of these areas is also reduced among these individuals (Durazzo et al. 2010) . However, these studies have all employed treatment-as-usual paradigms, in which subjects were recruited from addiction clinics where they received individually varying treatment before or after the scan that sometimes included medication and was not placebo-controlled.
Only one previous neuroimaging study of medication effects on alcohol cue reactivity has combined imaging with the methodological rigor and detailed follow-up of a randomized clinical trial (RCT) (Langosch et al. 2012) . In response to this gap in the literature, we incorporated an established fMRI cue reactivity paradigm (Myrick et al. 2004 (Myrick et al. , 2008 (Myrick et al. , 2010 Schacht et al. 2011a Schacht et al. , 2013b ) into a 6-week double-blind RCT of a combination of two γ-aminobutyric acid (GABA)-ergic and glutamatergic medications, gabapentin (GBP) and flumazenil (FMZ), among treatment-seeking alcoholic adults. We have previously shown that GBP, a GABA analogue that impedes excitatory calcium currents (Hendrich et al. 2008 ) and may reduce glial glutamate production (Bonnet et al. 1999) , effectively reduces alcohol withdrawal (AW) symptoms ) and, in combination with naltrexone, reduces drinking more than naltrexone monotherapy, particularly among individuals who experience AW at study entry or who have a history of inpatient alcohol detoxification (Anton et al. 2011 ). Since AW is associated with reduced GABA tone and increased glutamatergic signaling (Cagetti et al. 2003; Tsai et al. 1998) , GBP is likely to be more effective among individuals with higher AW. In combination with FMZ, an antagonist at the GABA A receptor benzodiazepine site, GBP may shift the subunit composition of GABA A receptors to an arrangement that is more responsive to GABA signaling (Biggio et al. 2007; Sanna et al. 2003) . Accordingly, our RCT demonstrated, as we had hypothesized, that a combination of oral GBP and two FMZ infusions interacted with subjects' AW severity at study entry in its effect on drinking: subjects who received these medications and who had higher initial AW drank less, as did subjects who received placebos but had lower initial AW ).
The current study, which was part of the previously published RCT ), had two goals: (1) to analyze the effects of a GBP/FMZ combination, subjects' initial AW severity, and the interaction of these factors on alcohol cue-elicited brain activation and (2) to analyze associations between cue-elicited activation and drinking during the RCT. We predicted that the neuroimaging data would be consistent with the RCT outcomes, such that subjects treated with GBP/FMZ who had higher initial AW and those treated with placebos who had lower initial AW would demonstrate reduced cue-elicited activation in brain areas that had previously displayed susceptibility to pharmacological suppression of such activation. Further, we predicted that greater cue-elicited activation of one or more of these areas would be associated with an increased likelihood of drinking during the weeks after the scan.
Materials and methods

Overview
Subjects were randomized, based on their initial AW severity, to either a combination of oral GBP for 39 days (6 weeks) and FMZ infusions on the first 2 days (the Prometa protocol; Hythiam, Inc., Los Angeles, CA, USA) or an oral placebo and placebo infusions on the same timecourse. During the second or third week of treatment (mean scan day = day 15; SD=2.5 days), subjects were administered an alcohol cue reactivity task during an fMRI scan. All procedures were approved by the Institutional Review Board for Human Research at the Medical University of South Carolina.
Subjects
Subjects were recruited through media advertisements. Inclusion criteria were (1) age 18-70 years; (2) DSM-IV (American Psychiatric Association 2000) alcohol dependence diagnosis, as assessed by the Structured Clinical Interview for DSM-IV-TR (SCID; First et al. 2002) ; (3) minimum of five drinks per day on 70 % of days in the month before screening; and (4) last drink no more than 72 h before medication randomization. Exclusion criteria were (1) any other Axis I diagnosis, as assessed by SCID; (2) past month use of any substance except marijuana or nicotine, as assessed by selfreport and urine drug screen (UDS); (3) history of seizures or delirium tremens during AW, as assessed by self-report; and (4) use of any psychoactive medication, including benzodiazepines, in the previous 2 weeks or use of zolpidem or zaleplon more than three times in the previous 2 weeks. Although recent marijuana use was not exclusionary, individuals were required to have a negative UDS for Δ 9 -tetrahydrocannabinol (cutoff, 50 ng/ml) before beginning medication.
Of the 60 individuals who met these criteria and participated in the larger trial, 4 subjects had MRI contraindications and 3 more dropped out of the study before the scan session. Of the 53 individuals who were scanned, 3 were subsequently excluded from analysis for excessive head motion (see the succeeding subsections), 1 was excluded because she was not scanned until day 28, and 1 was excluded because he was court-ordered to alcohol treatment (a protocol violation), yielding a final sample of 48. Following the scan session, 2 subjects dropped out before their next (week 3) appointment and 3 more subjects dropped out between the week 3 and 4 appointments, leaving 43 subjects with complete drinking data for the 6-week trial. The AW and medication groups for these subsets of subjects are listed in Table 1 , and demographic and drinking variables for the 48 scanned subjects are listed in Table 2 .
Assessment and randomization
Inclusion and exclusion criteria were initially assessed by phone, after which prospective subjects were invited to the laboratory for further assessment, where, before assessment began, they provided informed consent. Assessments included the SCID, the Alcohol Dependence Scale (ADS; Skinner and Allen 1982) , and the Obsessive Compulsive Drinking Scale (OCDS; Anton et al. 1996) . Eligible subjects were then scheduled for their first treatment appointment (day 1) and instructed to abstain from alcohol the night before the appointment. On day 1, subjects were administered the Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) (Sullivan et al. 1989 ), a clinician-administered rating scale for AW symptoms (range, 0-67). To ensure equal distribution of individuals with higher AW between medication groups, CIWA-Ar scores were subsequently used as an urn variable for medication randomization. Urn randomization assigns subjects to treatment groups randomly, with the exception that the assignment is biased toward balance in the various covariate (urn variable) combinations (Stout et al. 1994) . Subjects with CIWA-Ar scores ≥7 (higher AW group) were considered to have clinically significant AW and were approximately evenly randomized to active medications vs. placebos, as were subjects with CIWA-Ar scores <7 (lower AW group). As the medication combination assessed here is designed for outpatient administration (Urschel et al. 2007 ), the cutoff of 7 was chosen to reflect the level of AW severity typically seen in outpatient alcohol treatment settings, rather than the cutoff of 10 originally proposed for inpatient alcohol detoxification (Sullivan et al. 1989 ).
Medications
The treatment procedure, including detailed time-courses of the FMZ infusions and GBP titration and taper, is fully described in Anton et al. (2009) . Briefly, on day 1, subjects were administered either FMZ (2 mg) or sterile saline intravenously. Before leaving the laboratory, subjects were provided with GBP (300 mg) or identically packaged placebo and were instructed to take the medication orally at bedtime. Subjects returned to the laboratory on day 2, and the infusion procedure was repeated. After the infusions were complete, all subjects returned to the laboratory weekly for six appointments, during which their drinking was assessed with the Timeline Follow-back (TLFB; Sobell and Sobell 1992) and they received a manualized therapy session (combined behavioral intervention ; Miller 2004) . At the week 1, 3, and 6 visits, subjects were also administered the OCDS again. GBP was increased to 1,200 mg by day 4 (day 1, 300 mg; day 2, 600 mg; day 3, 900 mg) and was tapered from days 31 to 39.
Alcohol cue reactivity task
At the scan session, subjects were breathalyzed to ensure that they had not recently consumed alcohol and were again administered the CIWA-Ar. No subject had a breath alcohol level >0 or a CIWA-Ar score >3. Subsequently, subjects were positioned supine in the scanner and administered a 720-s-long alcohol cue reactivity task consisting of 24 pseudorandomly interspersed blocks of alcoholic beverage images (ALC), nonalcoholic beverage images (BEV), blurred versions of both of these types of images that served as visual controls, and a fixation cross (REST). Each 24-slong block was composed of five individual pictures, each displayed for 4.8 s, and was followed by a 6-s washout period intended to allow the hemodynamic response from the previous block to decline before the next was presented. Images were selected from a normative set (Stritzke et al. 2004) , supplemented with images from advertisements, and matched for intensity, color, and complexity. Alcohol image blocks were equally distributed between images of beer, wine, and liquor. In past versions of this task (Myrick et al. 2004 (Myrick et al. , 2008 (Myrick et al. , 2010 Schacht et al. 2011a Schacht et al. , 2013b , subjects were administered a sip of alcohol immediately before the scan. However, because subjects in this study were engaged in treatment, no alcohol was administered.
Image acquisition and preprocessing
Functional images were acquired with a 3-T Philips (Amsterdam, Netherlands) Interra scanner, using a gradient echo, echo planar imaging scan sequence. Three subjects had >2 mm of translational or 2°of rotational movement during the scan and were excluded from further analysis. Images were also spatially whitened with a global autoregressive filter to account for temporal correlations between spatially adjacent voxels. To eliminate lowfrequency noise in the blood oxygen level-dependent (BOLD) signal, a high-pass filter with a period of 240 s was used. A boxcar function representing stimulus presentation and duration times was then convolved with a canonical hemodynamic response function to create a basis function for general linear modeling (GLM). To eliminate task-correlated motion, for each subject, the six motion parameters from the realignment were also included in this first-level model.
Statistical analysis
To examine the effects of medication, initial AW severity, and their interaction, a contrast image of the difference in activation between alcoholic and nonalcoholic image blocks (ALC-BEV) was obtained for each subject, and these images were entered into a second-level whole-brain GLM that included medication group (GBP/FMZ vs. placebos), AW group (higher vs. lower), and their interaction. To avoid overfitting the second-level models, only age and the number of treatment days before the scan were included as covariates. However, a model in which age and gender were 23.1 (25.5) 8.4 (13.0) 4.6 (9.7) Lower AW > higher AW, p=0.04
All figures, except N, are presented as the means (standard deviations). Pre-scan and post-scan drinking data represent the percentage of heavy drinking days for each subject before vs. after that subject's scan ADS Alcohol Dependence Scale, OCDS Obsessive Compulsive Drinking Scale, n.s. not significant a Excludes participants who dropped out after the scan (N=5; 1 from the low AW/placebo group, 3 from the low AW/GBP/FMZ group, and 1 from the higher AW/GBP/FMZ group) covaried was also tested; its results were not significantly different from those reported below. To examine the relationship between ALC-BEV activation and drinking after the scan, for each subject, the percentage of days after the scan on which that subject drank heavily (percent heavy drinking days [%HDD] , >5 drinks in a day for men or 4 drinks in a day for women), as assessed by TLFB, was subsequently entered as a covariate in a whole-brain GLM that also included medication group, AW group, and the interaction of these factors. To account for the effect of recent drinking behavior (i.e., to determine activation related specifically to future drinking), %HDD during the treatment days before the scan was also covaried, as were age and the number of treatment days before the scan.
All analyses were corrected for multiple comparisons with a voxelwise height threshold of p<0.001, an extent threshold of 15 voxels, and a family-wise error (FWE) cluster-corrected whole-brain threshold of p < 0.05. Anatomic localization of significant clusters was performed with the Talairach Daemon database (Lancaster et al. 2000) . To follow-up significant interactions and further interrogate associations between brain activation and drinking, the time-course of the BOLD signal was extracted from all of the voxels in significant clusters and entered as the dependent variable in a hierarchical linear model (HLM), using HLM v.6.0.8 (Scientific Software International, Inc., Skokie, IL, USA). The order, onset, and duration of presentation of the cue reactivity task stimuli were entered as firstlevel independent variables in these models, which yielded an estimate of ALC-BEV activation in each significant cluster for each subject. These estimates were then used to produce group averages and scatter plots.
Results
Behavioral data
There were no significant differences in medication or AW group assignment between subjects randomized to medication and those who were scanned (χ 2 (3, N=60)=1.42, p= 0.70), those with usable scans (χ 2 (3, N=60)=1.55, p=0.67), or those with usable scans who completed the study (χ 2 (3, N=60)=1.86, p=0.60). Among subjects with usable scans, there were no significant differences between medication or AW groups in demographic variables, alcohol dependence severity, or pretreatment %HDD, but the higher AW group had significantly higher OCDS scores than the lower AW group (t(46)=−5.69, p=0.001) (see Table 2 ). The higher AW group also had significantly less %HDD than the lower AW group before (t(43.2)=−3.42, p=0.001, equal variances not assumed) and after (t(37.4) = −2.19, p = 0.04, equal variances not assumed) the scan. More detailed behavioral data for the full sample are presented in Anton et al. (2009) and Schacht et al. (2011b) .
Main effect of ALC-BEV activation
Across all subjects, regardless of initial AW status or medication, ALC images elicited greater activation than BEV images in a variety of brain areas, including mPFC, superior frontal gyrus, bilateral insula, PCC, and ACC (see Fig. 1 and Table 3 ).
Effects of AW and medications
There were no main effects of initial AW status or medication, but there was a significant interaction between these factors, such that subjects with higher AW who received GBP/FMZ and those with lower AW who received placebos demonstrated greater cue-elicited activation, relative to the other groups, in a cluster that encompassed dorsal anterior cingulate cortex (dACC) (FWE-corrected cluster probability of p=0.012; 99 voxels; local maxima at [−3, 39, 18] and [6, 33, 9] ) (see Fig. 2 ). All simple effects for this interaction were significant (i.e., in the GBP/FMZ group, higher AW subjects had significantly greater activation, while in the placebo group, lower AW subjects had greater activation; and among higher AW subjects, those who received GBP/FMZ had greater activation, while among lower AW subjects, those who received placebos had greater activation). Because the cluster of interest encompassed dACC, an area that is susceptible to task-related deactivation, ALC-REST and BEV-REST activations were also analyzed within this cluster. Across all subjects, there was greater activation in the REST condition than either the ALC or BEV conditions, and the magnitude of deactivation for these contrasts differed significantly by AW and medication groups (see Fig. 2 ). Relative to the other groups, the higher AW/GBP/FMZ and lower AW/placebos had both significantly less ALC-REST deactivation (F(1, 42)=14.24, p< 0.001) and significantly greater BEV-REST deactivation (F (1, 42)=4.29, p=0.045).
Because the groups with greater ALC-BEV activation and BEV-REST deactivation and less ALC-REST deactivation in dACC were the same ones with reduced drinking throughout the trial, we speculated that this region might underlie resistance to cue-elicited craving. To further explore this possibility, we examined the correlation between dACC ALC-BEV activation and subjects' OCDS scores from week 3 (i.e., the visit closest in time to the scan session). The correlation between dACC activation and total OCDS score approached significance (r(45)=−0.27, p= 0.08). Given this trend, we further evaluated the three empirically derived factors of the OCDS (Roberts et al. 1999) after removing the items related to alcohol consumption (which was already known to differ between treatment groups). This revealed a significant inverse correlation between dACC activation and the resistance/control impairment factor (r(45)=−0.31, p=0.04), such that subjects with greater activation (i.e., less deactivation to alcohol cues) reported significantly more control over drinking-related thoughts and impulses. The correlation between dACC activation and the OCDS obsession factor approached significance (r(45) = −0.28, p = 0.06), such that subjects with greater activation reported less frequent and less impactful drinking-related thoughts and drives, while the correlation with the interference factor was not significant (r(45)= −0.19, p=0.21).
Association with drinking
Controlling for initial AW status, medication, and their interaction, as well as for pre-scan %HDD, age, and the number of treatment days before the scan, post-scan %HDD was positively correlated with ALC-BEV activation in a cluster that encompassed the left middle frontal and precentral gyri (i.e., DLPFC) (FWE-corrected cluster probability of p=0.03; 78 voxels; local maxima at [−36, 6, 30] and [−39, 9, 42] ) (see Fig. 3 ), such that subjects with greater activation in this cluster had greater post-scan %HDD. The partial correlation between DLPFC activation and post-scan %HDD was r(40)=0.63 and did not significantly differ by medication or AW group. Across all subjects, the ALC-REST contrast was positive in this cluster (t(42)= 4.95, p < 0.001), while the BEV-REST contrast was negative (t (42)= −2.91, p= 0.006). Both contrasts correlated with post-scan heavy drinking, but in opposite directions: ALC-REST activation was positively associated with post-scan drinking (r(40)=0.44, p=0.003), while BEV-REST activation was negatively associated with postscan drinking (r(40)=−0.38, p=0.01).
Discussion
These data add to the nascent literature regarding medication effects on alcohol cue-elicited brain activation and the relationship between this activation and drinking behavior. Regarding the absence of main effects of medication or AW status, the former is consistent with a recent report that another GABA-ergic and glutamatergic medication, acamprosate, did not affect alcohol cue-elicited activation (Langosch et al. 2012) . No previous studies have examined AW effects on cue-elicited activation, although repeated T max value of the t statistic for each local maximum Fig. 1 Main effect of ALC-BEV activation. Across all subjects, alcohol cues, relative to neutral beverage cues, elicited greater activation in the medial prefrontal cortex (mPFC), superior frontal gyrus (SFG), insula, and anterior cingulate cortex (ACC), and posterior cingulate cortex (PCC). Colors correspond to the value of the t statistic for the ALC-BEV contrast alcohol detoxifications have been associated with alterations in cortical modulation of emotional perception (O'Daly et al. 2012) . The hypothesis that cue-elicited activation would be attenuated in the treatment groups with relatively reduced drinking in the RCT (i.e., the higher AW/GBP/FMZ and lower AW/placebo groups) was not supported; in fact, these groups displayed greater dACC activation, which was associated with greater control over drinking-related thoughts. Furthermore, across all subjects who completed the RCT, irrespective of AW status and/or medication, greater left DLPFC activation was prospectively associated with more frequent heavy drinking. The finding of greater ALC-BEV activation (reflecting attenuated ALC-REST deactivation and greater BEV-REST deactivation) in dACC among groups with reduced drinking raises several issues. ALC-BEV dACC activation was modestly associated with greater control over drinkingrelated thoughts and could thus reflect an adaptive response that contributed to these groups' better treatment outcome. The dACC has been implicated in cognitive, rather than affective, information processing (Bush et al. 2000) and is believed to underlie cognitive control (Paus 2001 ) and response inhibition (the suppression of a prepotent behavior) (Garavan et al. 2002; Matthews et al. 2004 ). These functions are compelling because, upon exposure to factors that increase motivation to drink, abstinent alcoholics who intend to stay sober may mobilize coping skills, including attempts to inhibit craving (Monti et al. 2000) . It should be noted that all subjects in the current study received six sessions of combined behavioral intervention (Miller 2004) , which explicitly addresses resistance to craving and other cognitive coping strategies. In addition, GBP has been reported to reduce cue-elicited alcohol craving (Mason et al. 2009 ), and smokers who are instructed to resist cigarette craving during cigarette cue exposure display increased cue-elicited dACC activation (Brody et al. 2007 ). Further, heavy drinkers demonstrate greater dACC activation during restrained choices in a delay-discounting task (Claus et al. 2011) . However, since between-group differences in dACC ALC-BEV activation in the current study reflected discrepant task-related deactivation, it is also possible that these differences represent another phenomenon. The dACC is a component of the default mode network, a group of functionally connected regions that demonstrate deactivation during task performance and activation at rest (Fox et al. 2005) . Among substance-dependent individuals, enhanced cue-elicited dACC deactivation has been positively associated with substance use (Goldstein et al. 2009) , and the strength of resting state functional connectivity between dACC and the ventral striatum has been positively associated with dependence severity (Hong et al. 2009 ). Thus, attenuated deactivation of dACC during ALC stimuli, relative to rest, may indicate relative recovery of normal function in this area. The association between such preservation and greater cognitive control, while exploratory, is consistent with this theoretical construct and should be explored in future research. The correlation between heavy drinking after the scan and cue-elicited DLPFC activation might be interpreted in light of the purported function of this region. DLPFC has reciprocal projections to the striatum and other subcortical nuclei and is believed to underlie selective attention and the maintenance of information in working memory (Petrides 2005) . In the processing of reward-related stimuli, it may integrate reward histories with contextual information about reward likelihood (Park et al. 2010) . Alcohol cue-elicited DLPFC activation has been correlated with in vivo alcohol craving (for a review, see Schacht et al. 2013a) , and disruption of DLPFC activity with transcranial direct current stimulation reduces craving (Boggio et al. 2008) . Across many substances of abuse, cue-elicited DLPFC activation has been found most frequently in non-treatment-seeking individuals, suggesting that such activation may be modulated by perceived drug use opportunity and may represent the generation and maintenance of drug-seeking behavioral goals (Wilson et al. 2004) . The association between DLPFC activation and relapse drinking among treatmentseeking subjects in this study supports this putative function in alcohol cue processing.
The only previous studies to note an association between alcohol cue-elicited activation and prospective risk of relapse reported greater mPFC activation among relapsers (Beck et al. 2012; Grüsser et al. 2004) . Two factors may account for the fact that the current study did not replicate this finding. First, subjects in the prior studies had undergone inpatient alcohol detoxification and had been abstinent for 3 to 7 weeks before imaging; most subjects in the current study drank heavily up until medication randomization, and some had additional heavy drinking days between randomization and the scan. Thus, cue-elicited mPFC activation may be associated with relapse risk after treatment, while DLPFC activation may be associated with such risk during treatment. Further, Beck et al. (2012) defined relapse as at least one heavy drinking day during 3 months of follow-up. When we defined relapse in this manner (i.e., at least one heavy drinking day after the scan), we found no differences between relapsers and nonrelapsers in the mPFC, DLPFC, or elsewhere (data not shown), suggesting that continuous definitions of relapse may reveal associations obscured by dichotomization of this variable.
This study had several important strengths and limitations. It represents one of the first attempts to incorporate a functional neuroimaging paradigm into an RCT and thus illustrates some challenges in integrating these kinds of research. As is often true of both kinds of research, the sample size was relatively small, especially in the higher AW group, in which women (N=3, of whom only one received GBP/FMZ) were particularly underrepresented. Although the sample was representative of the relatively low prevalence of clinically significant AW, particularly among women (Caetano et al. 1998) , future research in this area should aim for a larger number of individuals with higher AW. Further, subjects who dropped out after the scan (N=5) were excluded from the heavy drinking association analysis; while these subjects might have relapsed to their pre-scan drinking behavior, we did not know their reasons for dropping out. Finally, while most (70 %) of the remaining subjects had at least one post-scan heavy drinking day, the distribution of post-scan %HDD was right-skewed. Logarithmic transformations of this variable intended to produce more symmetric distributions did not change the An additional caveat is that, unlike previous iterations of our alcohol cue reactivity task, subjects were not administered any alcohol before visual stimuli were presented, as they were actively engaged in treatment. This change might explain the lack of cue-elicited VS activation among the placebo group (data not shown), which we had previously reported in five of the six studies that employed this task among non-treatment-seeking alcoholics, and might thus have reduced the ability to detect differences in VS activation between treatment groups. Some theories of DA signaling in VS hold that it represents a reward prediction signal (Schultz et al. 1997) ; thus, to the extent that the BOLD signal in VS represents DA signaling, its absence here may reflect alterations in reward prediction when alcohol-related pictures were not accompanied by the taste of alcohol. Given recent reports of lower cue-elicited and alcohol-induced VS activation among heavier drinkers, relative to lighter drinkers (Gilman et al. 2012; Vollstädt-Klein et al. 2010) , it is also possible that activation in this area was not observed because subjects in this study were heavydrinking, treatment-seeking alcoholics. Some theories of addiction posit a downregulation of DA function after chronic heavy alcohol use, especially after AW (Koob et al. 1998 ), leading to hyporesponsivity to alcohol cues in brain areas with heavy DA innervation. Only direct comparisons between early stage and late-stage alcoholics will completely resolve this issue.
Conclusions
This study combined functional neuroimaging with an RCT of an investigational pharmacotherapy for alcohol dependence. Considered alone, neither a GBP/FMZ combination nor subjects' initial AW status affected alcohol cue-elicited brain activation. However, these factors interacted in their effects, such that subjects who received GBP/FMZ and had higher initial AW and those who received placebos and had lower AWthe same groups that had less subsequent drinkingdemonstrated greater cue-elicited dACC activation, which reflected differences in deactivation between alcohol and beverage stimuli. This finding could suggest greater resistance to cue-elicited craving among these groups. Regardless of medication or initial AW status, DLPFC activation was positively associated with postscan heavy drinking. These results need replication, and the association between these areas of cue-elicited activation and relapse potential require further exploration. Overall, the integration of functional neuroimaging paradigms into clinical research offers a unique opportunity to better understand treatment effects on the brain and the predictive value of neuroimaging data for treatment success.
